Implications of the Affordable Care Act on Life Sciences Dealmaking

The Les Insights | By Todd C. Davis

The Patient Protection and Affordable Care Act (ACA) is the most significant piece of healthcare legislation since the passage of Medicare and Medicaid nearly fifty years ago, as it sets to transform nearly one-fifth of the nation’s GDP. Leading experts from The Wharton School of the University of Pennsylvania, Bristol-Myers Squibb, HealthCare Royalty Partners, Osage Partners and Defined Health discussed the implications of the ACA on life sciences dealmaking at this year’s LES 2013 Annual Meeting.